Werewolf Therapeutics (NASDAQ:HOWL) Announces Earnings Results

Werewolf Therapeutics (NASDAQ:HOWL) announced its quarterly earnings results on Tuesday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03), Zacks reports. Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%.

Werewolf Therapeutics Stock Up 2.9 %

Shares of NASDAQ:HOWL opened at $1.26 on Wednesday. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29. The business has a fifty day moving average of $1.37 and a two-hundred day moving average of $1.83. The stock has a market cap of $56.15 million, a P/E ratio of -0.82 and a beta of 0.37. Werewolf Therapeutics has a 52-week low of $1.03 and a 52-week high of $6.89.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. JMP Securities decreased their price target on Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating for the company in a report on Tuesday, January 14th. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a report on Tuesday, November 19th.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.